A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes.

Lenalidomide will be administered per os.

Dexamethasone will be administered intravenously or per os.

Nirogacestat will be administrated each day for all subsequent cycles were Blmf is also administrated.